All In Biotech

Drug Trial Radar · NCT07923162

MACE and BTK Inhibitors

Differential Risk of Hospitalization for MACE Across BTK Inhibitors: a Nationwide Target Trial Emulation Study

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Feb 1, 2027

Study completion Mar 1, 2027

Sponsor

Lead sponsor
University Hospital, CaenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Poitiers University Hospital
First posted
Nov 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bruton's tyrosine kinase inhibitors (BTKis) have demonstrated substantial therapeutic efficacy across multiple B-cell malignancies. Their durable hematologic benefits confer a favorable benefit-risk profile compared with other treatments, positioning BTKis as a cornerstone of therapy in several B-cell malignancies. However, BTKis are associated with an increased risk of cardiovascular (CV) adverse events, ranging from common complications such as atrial fibrillation (AF) and hypertension to more severe outcomes, including ischemic MACE. Accumulating evidence suggests that while CV toxicity is a class effect of BTKis, the incidence, magnitude, and risk of these events vary according to the specific agent used. Modest changes in systolic blood pressure or AF incidence and risk have been reported across BTKis in indirect comparisons; however, the clinical relevance of these findings remains uncertain, making it questionable to base BTKi selection solely on such differences. Moreover, if hematologic efficacy is assumed to be broadly comparable across BTKis and CV toxicity becomes the primary determinant of treatment choice, it would be logical to rely on robust, standardized CV endpoints traditionally used in the evaluation of CV therapies. Taken together, these considerations highlight the need for direct comparisons between available BTKis to generate more robust cardiovascular evidence and ultimately guide hematologists toward selecting the least cardiotoxic agent. Although randomized controlled trials (RCTs) would be the ideal approach to address this question, no existing RCTs directly compare BTKis with cardiovascular events as a primary outcome. Recently, no significant differences in the risk of non-fatal MACE were observed among ibrutinib, acalabrutinib, and zanubrutinib, based on a network meta-analysis of safety outcomes from phase 3 RCTs primarily designed to assess BTKi efficacy . In this context, target trial emulation using observational data and propensity score-based methods offers a valuable alternative, enabling the generation of high-level evidence that closely approximates randomized conditions. The primary objective of this study will therefore be to compare the risk of hospitalization for MACE among the three BTKis (ibrutinib, acalabrutinib, zanubrutinib) in patients with B-cell malignancies, using a nationwide target trial emulation framework based on the French National Health Data System (SNDS), which covers 98.8% of the French population.

Conditions

  • Hematologic Cancer
  • MACE
  • BTK Inhibitors

Interventions

  • ibrutinibDrug

    patients exposed to ibrutinib

  • AcalabrutinibDrug

    patients exposed to acalabrutinib

  • ZanubrutinibDrug

    patients exposed to zanubrutinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. risk of hospitalization for MACETime frame: 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Caen-Normandy University Hospital

    Caen, Normandy, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.